<% ADLIST_MEGA section={"sectionId":"TOPBANNER","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"NEWS1","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"NEWS2","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"NEWS3","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"NEWS4","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"NEWS5","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"NEWS6","pickFromSponsorship":true,"pickFromHorizontal":true} section={"sectionId":"FEATUREDCONTENT","pickFromSponsorship":true,"pickFromHorizontal":true} issueId=FF7C4032-A4CE-4CB7-A1FF-7C67C0D8F470%>
Findings promising for PET imaging agent flutemetamol | Prostate cancer trial will combine Alpharadin with Provenge | ACRO urges FDA to expedite modernizing clinical trials
<% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=TOPBANNER %>
April 27, 2012
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
SIGN UP ⋅   FORWARD
<% ADLIST_BEGIN %>
Top Story
[[ logo ]]
Top Story
<% ADLIST_END sectionId=NEWS1 ISLOGO %>
<% ADLIST_BEGIN %><% ADLIST_END sectionId=NEWS1 MEDIUM_RECTANGLE %>
Findings promising for PET imaging agent flutemetamol
Findings from four pooled studies of brain biopsies showed the experimental PET imaging agent F-18 flutemetamol to have 93% sensitivity and 100% specificity in detecting beta amyloid plaque, which has been linked to Alzheimer's disease. Results of a brain autopsy study showed the agent diagnosed amyloid with an 86% sensitivity and 92% specificity.
AuntMinnie.com (free registration) (4/26) 
LinkedIn Twitter Facebook Google+ Email
<% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=NEWS1 %>
<% ADLIST_BEGIN %>
Clinical News & Research
[[ logo ]]
Clinical News & Research
<% ADLIST_END sectionId=NEWS2 ISLOGO %>
<% ADLIST_BEGIN %><% ADLIST_END sectionId=NEWS2 MEDIUM_RECTANGLE %>
Prostate cancer trial will combine Alpharadin with Provenge
In this video, Dr. Oliver Sartor of the Tulane Cancer Center in New Orleans explains a new trial approach that will use radiopharmaceutical radium-223 chloride, or Alpharadin, with the immunotherapy sipuleucel-T, or Provenge, to treat castration-resistant prostate cancer. Sartor said Alpharadin can release antigens, which makes cancer cells more vulnerable to treatments such as Provenge.
OncLive (4/25) 
LinkedIn Twitter Facebook Google+ Email
 
ACRO urges FDA to expedite modernizing clinical trials
The Association of Clinical Research Organizations asked the FDA to accelerate the modernization of regulations covering U.S. clinical trials. Though there have been some advances in "developing basic building blocks," product development is still expensive, unproductive and slow, ACRO said. The group suggested the FDA hire a chief innovation officer who has the power to authorize new approaches to trials.
PharmaTimes (U.K.) (4/26) 
LinkedIn Twitter Facebook Google+ Email
<% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=NEWS2 %>
<% ADLIST_BEGIN %>
Industry Report
[[ logo ]]
Industry Report
<% ADLIST_END sectionId=NEWS3 ISLOGO %>
<% ADLIST_BEGIN %><% ADLIST_END sectionId=NEWS3 MEDIUM_RECTANGLE %>
Survey: Radiology leaders not confident about reimbursements
A Medical Imaging Confidence Index survey found that while radiology administrators expect to see growth in test volume and profit for January to June this year, they have "very low confidence" that Medicare reimbursements will be adequate. The survey involved 160 hospital imaging managers and directors.
AuntMinnie.com (free registration) (4/26) 
LinkedIn Twitter Facebook Google+ Email
<% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=NEWS3 %>
<% ADLIST_BEGIN %>
.
[[ fcSectionHeader ]]
[[ subHeader ]]
[[ logo ]]
[[ fcSectionHeader ]]
[[ subHeader ]]
LinkedIn Twitter Facebook Google+ 
LinkedIn Twitter Facebook Google+ 
94A57BF5-E8A1-4598-B740-5CB55226F136 FF7C4032-A4CE-4CB7-A1FF-7C67C0D8F470 #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; padding-left:15px; padding-right:15px; 14px
Click here to learn more about Featured Content
<% ADLIST_END sectionId=FEATUREDCONTENT %>
<% ADLIST_BEGIN %>
News from the Field
[[ logo ]]
News from the Field
<% ADLIST_END sectionId=NEWS4 ISLOGO %>
<% ADLIST_BEGIN %><% ADLIST_END sectionId=NEWS4 MEDIUM_RECTANGLE %>
Advocacy groups act as matchmakers for clinical trials
The Michael J. Fox Foundation for Parkinson's Research, the Alzheimer's Association, JDRF and other patient advocacy groups increasingly match patients with clinical trials. More than half of trials in Phase II or III fail to complete enrollment within original timelines, and each year, 11% of research sites don't enroll any patients, according to Tufts University's Center for the Study of Drug Development.
The Wall Street Journal (tiered subscription model) (4/23) 
LinkedIn Twitter Facebook Google+ Email
<% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=NEWS4 %>
<% ADLIST_BEGIN %>
.
Business Tips and Advice
Sponsored Content from American Express
[[ logo ]]
Business Tips and Advice
Sponsored Content from American Express
<% ADLIST_END sectionId=NEWS5 ISLOGO %>
<% ADLIST_BEGIN %><% ADLIST_END sectionId=NEWS5 MEDIUM_RECTANGLE %> <% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=NEWS5 %>
<% ADLIST_BEGIN %>
Health Policy
[[ logo ]]
Health Policy
<% ADLIST_END sectionId=NEWS6 ISLOGO %>
<% ADLIST_BEGIN %><% ADLIST_END sectionId=NEWS6 MEDIUM_RECTANGLE %>
Bill seeking stronger FDA oversight of medical devices advances
A Senate panel on Wednesday cleared a bill that would allow the FDA to evaluate the safety of approved medical devices and give conditional approvals dependent on further studies. The measure also would tighten the agency's 510(k) process that permits firms to prove the similarity of their devices to products already approved without needing extensive trials.
MassDevice.com (Boston) (4/25) 
LinkedIn Twitter Facebook Google+ Email
FDA, industry disagree on details of drug tracking program
Disagreements between the FDA and the health care industry could sink plans to establish a national system for tracking and tracing pharmaceuticals. A group of drug manufacturers, distributors and pharmacies says tracking drug lots rather than individual packages, as the FDA proposes, would be cheaper and simpler to implement.
Reuters (4/25) 
LinkedIn Twitter Facebook Google+ Email
<% ADLIST_BEGIN %> #D2232A 16px Helvetica bold color:#D2232A; font-size:16px; font-family:Helvetica; font-weight:bold; text-decoration:none; line-height:20px; display: block; #000000 14px Helvetica normal font-family:Helvetica; font-size:14px; color:#000000; line-height: 20px; <% ADLIST_END sectionId=NEWS6 %>
Advancing Health Care
GAO report urges CMS to boost Medicare anti-fraud efforts
The CMS on Tuesday issued a final rule intended to combat Medicare fraud and save almost $1.6 billion in costs over the next decade. A Government Accountability Office report, however, said more needs to be done and pressed the CMS to run pre- and post-payment claims evaluations and to address program vulnerabilities.
Healthcare IT News (4/24) 
LinkedIn Twitter Facebook Google+ Email
From SNMMI
Discover what's happening at this year's SNM Annual Meeting
The SNM Annual Meeting — June 9-13 in Miami Beach, Fla. — is quickly approaching. Be sure to check out these popular sessions of interest including: Meet The Author Poster Sessions, PET Boot Camp: Mind, Body, and Spirit, Application-Specific Molecular Imaging, SPECT/CT Imaging: Clinical Role and Applications, Hybrid Nuclear-Magnetic Resonance Imaging Technologies, and Cardiac PET and SPECT 2012, plus so much more. Make your plans today!
LinkedIn Twitter Facebook Google+ Email
SNM is going green!
SNM members: Would you prefer to read JNM, JNMT and/or Uptake online? Help SNM help the environment — opt out of receiving printed copies of some or all of your SNM publications. It's your choice!
LinkedIn Twitter Facebook Google+ Email
Learn more about SNMMI:
SNMMI | News & Publications | Meetings | Education
Membership | Support Education/Research in Your Field
  
  
Ideas are like rabbits. You get a couple and learn how to handle them, and pretty soon you have a dozen.
John Steinbeck,
American writer
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information